Home › Gilead lifted by $3.6B 1Q sales of newest hepatitis C pill
 

Keywords :   


Gilead lifted by $3.6B 1Q sales of newest hepatitis C pill

2015-05-01 02:36:04| Biotech - Topix.net

Gilead Sciences raked in $3.6 billion from sales of its newest hepatitis C pill, lifting the drugmaker's results past Wall Street expectations. Meanwhile, sales of Gilead's previous hepatitis C drug, Sovaldi, dropped 57 percent to $972 million.

Tags: c sales newest pill

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
12.05Spate Unveils the Top Sustainability Trends Cycling Google Searches
12.05Oh K! is the Most Searched Beauty Brand in the World: Cosmetify
More »